A case series of acquired immunodeficiency syndrome patients with initial neoplastic diagnoses of intraoral Kaposi's sarcoma.
BACKGROUND
Oral Kaposi's sarcoma (KS) may represent the initial clinical manifestation of immunosuppression in human immunodeficiency virus disease. This article reviews the treatment provided to these patients and the outcome of the disease and provides the opportunity to assess the impact of improvements in the medical therapy of acquired immunodeficiency syndrome on disease outcome.


METHODS
A tumor registry was examined to identify patients in whom oral KS was the first neoplastic diagnosis.


CONCLUSIONS
Thirty-seven cases of oral KS representing 1.9% of all cases of KS were identified as the first malignant diagnosis in patients with acquired immunodeficiency syndrome. Patients with oral KS have limited survival; the cause of death is either infection or malignancy. In our study, the palate was the most common site of primary involvement in the oral cavity. Recently diagnosed patients remained alive longer than those diagnosed earlier, and the patients with the most recently diagnosed cases were alive at the completion of the study, suggesting that medical management of human immunodeficiency virus has improved with new therapies.
Gorsky
M
M
University of British Columbia, Canada.
Epstein
J B
JB
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications* / Q000175:diagnosis; D000328:Adult; D001955:British Columbia / Q000453:epidemiology; D002423:Cause of Death; D006801:Humans; D008297:Male; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000175:diagnosis / Q000209:etiology* / Q000401:mortality / Q000628:therapy; D010157:Palatal Neoplasms / Q000175:diagnosis / Q000209:etiology / Q000401:mortality / Q000628:therapy; D012042:Registries; D012514:Sarcoma, Kaposi / Q000175:diagnosis / Q000209:etiology* / Q000401:mortality / Q000628:therapy; D015996:Survival Rate